Stay updated with breaking news from David Hung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NUV-1511 is the first clinical candidate from the company’s novel drug-drug conjugate platform Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024 ...
The season of giving is in full swing. Here's a guide to the best types of items to donate for toy drives, and what and who are usually forgotten.
NEW YORK--(BUSINESS WIRE)--Nov 13, 2023--
Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate clinical candidate...
02.11.2023 - Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended ...